Overview
Ursapharm Poland specializes in ophthalmic preparations, offering medicinal products, medical devices and dietary supplements. Its portfolio includes HYLO products for the care and treatment of dry eyes, POSIFORLID for the hygiene of irritated eyelid margins, and an azelastine nasal spray.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
URSAPHARM publishes initial study results on azelastine's antiviral effects
URSAPHARM announces research results on combating COVID-19 with azelastine
URSAPHARM and CEBINA start clinical trials on antiviral effects of azelastine nasal spray
URSAPHARM's superior quality – made in Germany
URSAPHARM becomes eye care partner of FC Bayern Munich
Industry
Bank accounts
Registered as a VAT taxpayer on 2010-06-14. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 151.9KPLN 151,868 |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $14,542$14,542 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 1, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $14,695$14,695 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $13,637$13,637 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Public sector contracts
Ursapharm Poland is the contractor in one public sector contract, worth PLN 1.22k.
| Public buyer | Value | |
|---|---|---|
| Centrum Medycznego Kształcenia Podyplomowego | PLN 1,217 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, two members of the management board jointly, or one member of the management board jointly with a commercial proxy, are authorised to submit declarations of will on behalf of the company, whereas the President of the Management Board and the Vice-President represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ursapharm Arzneimittel Gmbh | 100 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Aquaphor Polandsp. z o.o. | $20,476,362.41 | aquaphor.pl | ||
| SynektikS.A. | $20,028,244.70 | synektik.pl | ||
| Prosave.Plsp. z o.o. | $19,903,401.00 | prosave.pl | ||
| OwlieS.A. | $17,199,251.89 | owlie.pl | ||
| Biochem PolskaS.A. | $13,180,007.81 | biochempolska.pl | ||
| Przedsiębiorstwo Produkcyjno-Handlowo-Usługowe Citosp. z o.o. | $13,868,713.26 | cito.eu | ||
| PolypharmS.A. | $13,660,727.48 | polypharm.pl | ||
| Diather Petrusewiczsp. k. | $7,399,375.09 | diather.pl | ||
| Chem4polsp. z o.o. | $6,926,177.18 | chem4pol.pl | ||
| Bestpharmasp. z o.o. | $5,786,190.68 | bestpharma.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-11 | Address change (Malarska 6, 05-092, Łomianki → Ul. Wybrzeże Gdyńskie 27, 01-531, Warszawa) | |
| 2016-06-14 | PKD change (Removed: 10.89.Z, 20.53.Z, 20.59.Z, 46.17.Z, 46.75.Z, 74.90.Z) | |
| 2014-05-16 | Address change (Żywiczna 7, 05-092, Łomianki → Malarska 6, 05-092, Łomianki) | |
| 2013-10-22 | PKD change (Added: 46.17.Z, 46.39.Z) | |
| 2010-06-15 | Entered in the register |
FAQ
Last updated: 2026-10-07